TABE A5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE 

 TWO-YEAR FEED STUDY OF NITROFURANTOIN (Continued) 



Untreated Control 



Low Dose 



High Dose 



GENITAL SYSTEM (Continued) 

 Epididymis 



Atypical cells 



Degeneration 



Depletion 



Fibrosis 



Inflammation, granulomatous 

 Preputial gland 



Atrophy 



Fibrosis 



Hyperplasia 



Inflammation, suppurative 



Duct, cyst 

 Prostate 



Cyst 



Cyst, multiple 



Fibrosis 



Inflammation 



Inflammation, chronic 



Inflammation, chronic, focal 



Inflammation, suppurative 



Mineralization, focal 



Mineralization, multifocal 



Epithelium, hyperplasia 

 Seminal vesicle 



Atrophy 



Dilatation 



Fibrosis 



Mineralization 



Epithelium, hyperplasia 

 Testes 



Aspermatogenesis 



Atrophy 



Degeneration 



Hemorrhage 



Mineralization 



Arteriole, necrosis, fibrinoid 



Interstitial cell, hyperplasia 



Perivascular, infiltration cellular, 

 mononuclear cell 



(50) 



(50) 



3 (6%) 



1 (2%) 



24 (48%) 



1 (2%) 



(50) 



1 (2%) 



(50) 

 38 (76%) 

 41 (82%) 



1 (2%) 



1 (2%) 



1 (2%) 



4 (8%) 



3 (6%) 



8 (16%) 

 3 (6%) 



9 (18%) 



39 (80%) 



1 (2%) 

 1 (2%) 

 (50) 



8 (16%) 

 1 (2%) 



4 (8%) 



(50) 



44 (88%) 



48 (96%) 



36 (72%) 



15 (30%) 

 2 (4%) 



19 (38%) 



HEMATOPOIETIC SYSTEM 

 Blood 



Anemia 



Hypochromasia 



Polychromasia 

 Bone marrow 



Atrophy 



Hyperplasia, reticulum cell 



Myelofibrosis 



Myeloid cell, hyperplasia 

 Lymph node 



Inguinal, hyperplasia, lymphoid 



Mediastinal, angiectasis 



Mediastinal, congestion 



Mediastinal, hyperplasia, lymphoid 



Mediastinal, pigmentation, hemosiderin 



Pancreatic, hyperplasia, lymphoid 



Pancreatic, inflammation, granulomatous 



Pancreatic, mineralization 



Renal, angiectasis 



Renal, hyperplasia, lymphoid 



1 (2%) 



1 (2%) 

 1 (2%) 



(13) 

 1 (8%) 



1 (8%) 

 (50) 



2 (4%) 

 (50) 

 2 (4%) 



1 (2%) 

 1 (2%) 



1 (2%) 



1 (2%) 



(10) 



1 (10%) 

 (50) 



1 (2%) 



2 (4%) 



(50) 



1 (2%) 



2 (4%) 



2 (4%) 



1 (2%) 



1 (2%) 



1 (2%) 



4 (8%) 



3 (6%) 



Nitrofurantoin, NTP TR 341 



106 



